All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

FDA-&-EMA-New-Drug Approvals(Mid-2020 Recap)-insert

X

Find Clinical Drug Pipeline Developments & Deals by Tavotek Biotherapeutics

All Data

Filters

refresh

×

FILTER DATA :

Therapeutic Area

Study Phase

Country

News Type

Company

refresh

Companies By Therapeutic Area

Development Status

Tavotek Biotherapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Chinaplas 2020

Participation Not Confirmed

Update your events

Tavotek Inks Research Pact with Genmab to Develop Bispecific Antibodies using Duobody Technology Platform

Contact the Supplier

Lead Product(s): Bispecific antibodies

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Recipient: Genmab

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 25, 2020

Details:

The objective of the agreement is to develop a novel first-in-class immune-modulator bispecific antibody for auto-immune and inflammatory-related conditions, using DuoBody® technology, proprietary platform of Genmab A/S of Denmark.

Tavotek Biotherapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Chinaplas 2020

Participation Not Confirmed

Update your events

The alliance is aimed at co-developing a combination therapy of YS-ON-001/002 and Tavo-201/203 for cancer treatment.

Contact the Supplier

Lead Product(s): YS-ON-001,YS-ON-002,Tavo-201

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Yisheng Biopharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 06, 2020

Details:

The objective of the alliance is to co-develop a combination therapy of involving Yisheng's & Tavotek's lead assets YS-ON-001/002 and Tavo-201/203 for cancer treatment.